FDAsafety guidance83% confidence
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Agios Pharmaceuticals.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Hematology · Thalassemia
- Sub-indication
- General
Related signal: Agios Pharmaceuticals' Mitapivat Shows Promise in Non-Transfusion-Dependent Thalassemia Study